Dapagliflozin in Mangement of Pulmonary Hypertension Patients

Launched by ASSIUT UNIVERSITY · Sep 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called Dapagliflozin on patients with pulmonary hypertension, a condition that causes high blood pressure in the lungs. The trial aims to understand how this medication can improve the health and heart function of these patients. It will be conducted at Assiut University Hospital and is currently not recruiting participants.

To be eligible for this trial, participants must be at least 18 years old and have been diagnosed with pulmonary hypertension through specific tests. However, some individuals cannot join the study if they have low blood pressure, poor kidney function, significant liver issues, certain types of cancer, or other serious heart conditions. If selected, participants will have the chance to take Dapagliflozin and will be monitored to see how their condition improves. This study is important because it could help doctors find new ways to treat pulmonary hypertension and improve patients' quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • that the patients were diagnosed with pulmonary hypertension By Right heart cath OR suspected By Echocardiograghy according to the ESC guidelines for pulmonary hypertension that they were aged 18 years or older
• Exclusion Criteria:
• • 1. symptomatic hypotension (systolic blood pressure \< 95 mmHg)
• • 2. impaired renal function (eGFR \< 30 mL/min/1.73 m2 calculated according to the CKD-EPI formula) and serum potassium level \> 5.2 mmol/L
• • 3. hepatic dysfunction (defined as liver parameters such as ALT, AST, and/or ALP, which are three times above the upper 99-th percentile of the reference range
• • 4. biliary cirrhosis and cholestasis, active malignancies (regardless of the stage and type of malignancy)),
• • 5. the current use of hormone replacement therapy, chemotherapy, or immunotherapy
• • 6. Type 1 diabetes mellitus
• • 7. Acute pulmonary embolism (15)
• • 8. Signficant Primary valvular Heart disease
• • 9. Ischemic heart disease